HWN Suggests

Finally, Some Good News! The FDA Approved A New UTI Medication — Here's Why It's More Effective

As most girls have learned the hard way, getting a UTI is pretty much a rite of (vaginal) passage. In fact, uncomplicated urinary tract infections are the most common infection in women and can happen more than once in a woman’s lifetime simply because of the design of the female anatomy, according to the Mayo Clinic. For the people in the back: they also do not occur solely because of sex, though being sexually active could increase the chance of triggering one. So, long story short, if you’ve never had a UTI, good for you, God’s fave! If you have dealt with one or will deal with one, I also have some good news. For the first time in 30 years, the FDA has approved a new drug to treat UTIs.…

read full article

Featured

 Expert discusses unique mechanism of action of UTI treatment gepotidacin

There are therapies approved, but I think this one's a little different. It’s a new MOA [mechanism of action], and that's what's exciting about this treatment. Now, when we look at the clinical trial data, it was non inferior to currently available treatment options, which isn't a isn't a bad thing; it’s actually a positive thing, because now it shows that there is equitable data that gives another option, and a lot of times in the antibiotics, yes, you're looking for superiority, but a lot of times, what's another option that will really impede the resistance that we're seeing across the board? The exciting thing here is we still have nitrofurantoin, we still have fluoroquinolones, but how can we use this new option that might have a different side effect profile and leverage that for specific patient populations, then we can decrease resistance.

Articles of Interest

Clinical Implications, Study Takeaways of Gepotidacin For Uncomplicated UTIs

Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action.1 “it actually prevents bactericidal DNA replication by 2 distinct enzymes. One is the DNA gyrase, and the other is topoisomerase 4,” said Pamela Kushner, MD, clinical professor of Family Medicine for the University of California at Irvine. “And this is a distinct mechanism of action because it interrupts the catalytic activity of the DNA gyrase and topoisomerase, and this is at an earlier stage than fluoroquinolones...There is also no overlap of the FQ binding sites, and that's significant.”

Expert Insights: Q&A with Mark Ebell, MD, on Gepotidacin and UTI Management

Gepotidacin seems to be similar in efficacy to other first-line antibiotics including pivmecillinam, which was just approved in April 2024. The somewhat higher rate of GI side effects and the much higher cost make it a second- or third-line drug in my opinion.

FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections

Gepotidacin demonstrated non-inferiority in the EAGLE-2 trial and statistical superiority in the EAGLE-3 trial compared to nitrofurantoin, a standard treatment. With its novel mechanism and alternative side effect profile, gepotidacin offers another treatment option that could help decrease resistance and improve care for patients who don’t respond to existing therapies.

FDA Approves Gepotidacin (Blujepa) to treat Uncomplicated Urinary Tract Infections

Firstly, Gepotidacin selectively inhibits bacterial DNA replication by interacting with the bacterial subunits of DNA gyrase and topoisomerase IV. Additionally, Gepotidacin (Blujepa) acts as a reversible acetylcholinesterase inhibitor, as shown in in vitro laboratory studies. Furthermore, nonclinical studies have demonstrated its potent activity against a wide range of uropathogens, including those resistant to other antibiotics.

Gepotidacin Receives FDA Approval for uUTIs in Adult, Pediatric Female Patients

Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that prevents bacterial DNA replication through a distinct mechanism of action and a unique binding site, delivering well-balanced inhibition of 2 type II topoisomerase enzymes.

Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea

The ongoing spread of antimicrobial resistance has made the treatment of uncomplicated urinary tract infections (UTIs) and urogenital gonorrhoea increasingly difficult. New oral treatment options are urgently needed. Gepotidacin (previously GSK2140944) is a novel, bactericidal, oral, 'first-in-class' triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking two essential topoisomerase enzymes. Mutations in both enzymes would likely be necessary for resistance to occur...

Resources

Blujepa/Gepotidacin

Recommended Dosage for Female Adult and Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg. The recommended dosage of BLUJEPA is 1,500 mg (two 750 mg tablets) taken orally, twice daily (approximately 12 hours apart) for 5 days.